Comment on CMS-2026-1255-0001

Summary: AARP supports the proposed rule to improve interoperability and establish faster timelines for drug prior authorizations, emphasizing that these changes will reduce delays in patient care. They advocate for further strengthening the proposal by ensuring electronic prior authorization (ePA) is usable in real clinical workflows, requiring clear and actionable denial reasons for patients, and making public reporting data more accessible and standardized.